Bayer makes first move into condensates

January 9th, 2020 | Nature Biotechnology

German pharma Bayer has signed a $100 million deal with Dewpoint Therapeutics to jointly pursue biomolecular condensates for drug discovery. The companies will combine Dewpoint’s condensates expertise with Bayer’s small-molecules library to discover drugs for heart diseases and gynecological indications…

Full article